Physician profile
Daniel Fleksher
NPI 1235428897
$1,076.54
in general payments reported to CMS, 2019-2025
24 companies · $115 in 2025
The $115 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $541 · 2020: $82.62 · 2021: $16.84 · 2022: $133 · 2023: $62.15 · 2024: $126 · 2025: $115.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $303.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $303.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $206.25 | 2019-2024 | Breztri |
| Janssen Pharmaceuticals, INC | $149.16 | 2019-2020 | |
| Amgen INC. | $136.17 | 2019-2025 | Evenity, Prolia, Otezla |
| Pfizer INC. | $87.28 | 2019-2024 | |
| Lilly USA, LLC | $73.17 | 2019-2025 | Mounjaro, Zepbound |
| Sanofi-Aventis U.S. LLC | $43.11 | 2019-2020 | |
| Glaxosmithkline, LLC. | $39.20 | 2022-2024 | Arexvy, Shingrix |
| Exact Sciences Corporation | $38.82 | 2025 | The Cologuard Plus Collection Kit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $33.10 | 2023-2025 | Jardiance |
| Genzyme Corporation | $30.11 | 2019-2020 | |
| Phadia US INC. | $30.08 | 2019 | |
| Merck Sharp & Dohme LLC | $25.77 | 2019-2024 | Gardasil 9, Gardasil, Capvaxive |
| Azurity Pharmaceuticals, INC. | $18.76 | 2025 | Horizant |
| Biohaven Pharmaceutical Holding Company LTD. | $17.28 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $16.84 | 2021 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $16.08 | 2024 | |
| Novartis Pharmaceuticals Corporation | $15.99 | 2022 | |
| Sanofi Pasteur INC. | $15.26 | 2019 | |
| Gilead Sciences, INC. | $15.09 | 2019 | |
| Amarin Pharma, INC. | $14.99 | 2019 | |
| Novo Nordisk INC | $14.56 | 2023 | |
| Horizon Therapeutics Plc | $14.00 | 2020 | |
| Allergan, INC. | $12.78 | 2019 | |
| Abbott Laboratories | $12.69 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Fleksher listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.